Advanced Bionics enters SCS market with Precision
This article was originally published in The Gray Sheet
Executive Summary
PMA approval of the rechargeable spinal cord stimulation (SCS) implant for chronic pain April 28 marks entry into a $350 mil. U.S. market, the firm says. The PMA was supported by a literature review with safety data from 880 patients and efficacy results from 116 patients. The firm will compete primarily with Advanced Neuromodulation Systems and Medtronic, which offer Genesis and Itrel SCS, respectively. Precision is the first such device to offer rechargeability and "real-time" programming, Advanced Bionics claims...